FDA Panel to Review Popular Peptides Amid Surging Consumer Demand
This week, FDA advisers will evaluate whether seven popular peptides—including BPC-157, TB-500, and Semax—should be added to the agency's 503A Bulks List, which would allow state-licensed pharmacies to compound them for patients with prescriptions. The review comes as peptides transition from niche anti-aging clinics into the mainstream wellness market, fueled by social media influencers, biohacking communities, and public support from Health Secretary Robert F. Kennedy Jr., who has personally used them with "really good effect."